



Satiate

Research & Anatech Pvt. Ltd.

NABL ACCREDITED GOVT. APPROVED TESTING LABORATORY
 Plot No. 264, 1st & 2nd Floor, HSIIDC, Barwala-134118, Panchkula (Haryana)
 E-mail: satiateresearch@gmail.com, Website : www.sralabs.com



TEST REPORT

FDA Lic. No. : 25-LAB-HR

Form-39A, 150-E (f) Report of test or Analysis by Approved Institution For Procurement Agency

Name of sample	: Cefixime Tablet IP 200 mg	AR No.	: SA/GO-181225/004
Batch No.	: 0131	Batch Size	: NM
D/M	: 08/2025	D/E	: 07/2027
Original Manufacturer	: NM	Name of supplier	: NM
Mfg. Lic. No	: NM	Ref. No.(As in test request slip)	: NM
Sample Submitted By	: Medical Superintendent ESIC	Ref. No.(As given by party)	: NM
Address	: ESIC Pooluvapatti to Thirumurugan Poondi Ring Road Tiruppur - 641 603 Tiruppur - 641	Sample Quantity	: 70 Tablets
Date of receipt	: 17/11/2025	Sample received on	: 18/12/2025
Date of start of analysis	: 20/12/2025	Date of completion of analysis	: 24/12/2025
Protocol of test applied	: IP 2022	Date of Issue of the report	: 25/12/2025

TEST PARAMETERS	OBTAINED			LIMITS
Description	: White circular shaped biconvex film coated tablet plain surface on both sides.			
Average weight	: 293.65 mg			
Uniformity of weight	: Min Max -1.51 % +2.67 %			Limit ±5.0 % of average weight
Identification Test (By HPLC)	: Complies			To comply
Water	: 5.12 %			NMT 10.0 %
Dissolution Test (By UV)	: Min Max Avg			Limit
In Phosphate buffer pH 7.2	: 90.25 % 95.29 % 93.27 %			Q. NLT 75.00 %
Leak test	: Complies			To comply
Hardness	: 3.5 kg/cm ²			
CONTENTS		OBTAINED	CLAIM	LIMITS
Assay (By HPLC) :-				
Composition				
Each film coated tablet contains:-				
Cefixime IP				
(As trihydrate)				
Eq. to anhydrous Cefixime	199.47 mg	200.00 mg	(180.00 - 220.00) mg	IP 2022

In the opinion of the undersigned, the sample referred to above is of Standard Quality as defined in the Drugs and Cosmetics Act and the Rules made under for the reasons given below in respect to Test(s) mentioned above.

End of Report



Date : 25/12/2025

Person In-charge of Testing
 Dr. Surender Panghal (M.Pharma, Ph.D.)
 (Quality Manager)

Page : 1 of 1

Disclaimer :

Satiate Research & Anatech Pvt. Ltd. committed to maintain client (s) Privacy and confidentiality at our platform. Please note that the contents of this report and any attached documents, are confidential and intended solely for the mentioned client only. We are excited to share this report with our client and cannot be used in any advertising media without our special permission in writing. Reported results are related only to items tested/requested by client and only to the standards / procedures indicated on the report. Sample is not drawn by us unless otherwise stated. We want to clarify that there is no endorsement of the product implied or inferred. This report is not to be copied or reproduced in whole or in part and cannot be used as evidence in a court of law. Legal disputes are subjected to Panchkula jurisdiction only.



Satiate

Research & Anatech Pvt. Ltd.

NABL ACCREDITED GOVT. APPROVED TESTING LABORATORY
 Plot No. 264, 1st & 2nd Floor, HSIIDC, Barwala-134118, Panchkula (Haryana)
 E-mail: satiate@research@gmail.com, Website : www.sralabs.com



TEST REPORT

FDA Lic. No. : 25-LAB-HR

Form-39A, 150-E (f) Report of test or Analysis by Approved Institution For Procurement Agency

Name of sample	: Telmisartan Tablet IP 40 mg	AR No.	: SA/GO-181225/005
Batch No.	: 2508172	Batch Size	: NM
D/M	: 08/2025	D/E	: 07/2027
Original Manufacturer	: NM	Name of supplier	: NM
Mfg. Lic. No	: NM	Ref. No.(As in test request slip)	: NM
Sample Submitted By	: Medical Superintendent ESIC	Ref. No.(As given by party)	: NM
Address	: ESIC Pooluvapatti to Thirumurugan Poondi Ring Road Tiruppur - 641 603 Tiruppur - 641	Sample Quantity	: 70 Tablets
Date of receipt	: 17/11/2025	Sample received on	: 18/12/2025
Date of start of analysis	: 18/12/2025	Date of completion of analysis	: 24/12/2025
Protocol of test applied	: IP 2022 & IP Addendum 2024/Amendment List-07	Date of Issue of the report	: 25/12/2025

<u>TEST PARAMETERS</u>	<u>OBTAINED</u>			<u>LIMITS</u>
Description	: White circular shaped biconvex uncoated tablet plain surface on both sides.			
Average weight	: 222.58 mg			
Uniformity of weight	: Min Max -1.15 % +2.18 %			Limit ±7.5 % of average weight
Identification Test (By HPLC)	: Complies			To comply
Hardness	: 3.0 kg/cm ²			
Leak test	: Complies			To comply
Friability	: 0.12 %			NMT 1.0 %
Related substances (By HPLC)	:			
Any secondary impurity	: Not detected			NMT 0.2 %
Dissolution Test (By UV)	: Min Max Avg			Limit
In phosphate buffer (pH 7.5)	: 90.65 % 95.72 % 93.82 %			Q. NLT 75.00 %
Uniformity of content	: 95.18 % 100.32 % 98.82 %			
Acceptance value	: 3.8			NMT 15.0
<u>CONTENTS</u>	<u>OBTAINED</u>	<u>CLAIM</u>	<u>LIMITS</u>	<u>METHOD</u>
Assay	-			-
Composition	-			-
Each uncoated tablet contains:-				
Telmisartan IP	39.53 mg			IP 2022 & IP Addendum 2024/Amendment List-07
	40.00 mg			(36.00 - 44.00) mg

Disclaimer :

Satiate Research & Anatech Pvt. Ltd. committed to maintain client (s) Privacy and confidentiality at our platform. Please note that the contents of this report and any attached documents are confidential and intended solely for the mentioned client only. We are excited to share this report with our client and cannot be used in any advertising media without our special permission in writing. Reported results are related only to items tested/requested by client and only to the standards / procedures indicated on the report. Sample is not drawn by us unless otherwise stated. We want to clarify that there is no endorsement of the product implied or inferred. This report is not to be copied or reproduced in whole or in part and cannot be used as evidence in a court of law. Legal disputes are subjected to Panchkula jurisdiction only.



Satiate

Research & Anatech Pvt. Ltd.

NABL ACCREDITED GOVT. APPROVED TESTING LABORATORY
 Plot No. 264, 1st & 2nd Floor, HSIIDC, Barwala-134118, Panchkula (Haryana)
 E-mail: satiate.research@gmail.com, Website : www.sralabs.com



TEST REPORT

FDA Lic. No. : 25-LAB-HR

Form-39A, 150-E (f) Report of test or Analysis by Approved Institution For Procurement Agency

Name of sample	: Telmisartan Tablet IP 40 mg	AR No.	: SA/GO-181225/005
Batch No.	: 2508172	Batch Size	: NM
D/M	: 08/2025	D/E	: 07/2027
Original Manufacturer	: NM	Name of supplier	: NM
Mfg. Lic. No	: NM	Ref. No.(As in test request slip)	: NM
Sample Submitted By	: Medical Superintendent ESIC	Ref. No.(As given by party)	: NM
Address	: ESIC Pooluvapatti to Thirumurugan Poondi Ring Road Tiruppur - 641 603 Tiruppur - 641	Sample Quantity	: 70 Tablets
Date of receipt	: 17/11/2025	Sample received on	: 18/12/2025
Date of start of analysis	: 18/12/2025	Date of completion of analysis	: 24/12/2025
Protocol of test applied	: IP 2022 & IP Addendum 2024/Amendment List-07	Date of Issue of the report	: 25/12/2025

In the opinion of the undersigned, the sample referred to above is of Standard Quality as defined in the Drugs and Cosmetics Act and the Rules made under for the reasons given below in respect to Test(s) mentioned above.

End of Report

Person In-charge of Testing

Dr Surender Panghal (M.Pharma, Ph.D.)
 (Quality Manager)



Date : 25/12/2025

Disclaimer :

Satiate Research & Anatech Pvt. Ltd. committed to maintain client (s) Privacy and confidentiality at our platform. Please note that the contents of this report and any attached documents are confidential and intended solely for the mentioned client only. We are excited to share this report with our client and cannot be used in any advertising media without our special permission in writing. Reported results are related only to items tested/requested by client and only to the standards / procedures indicated on the report. Sample is not drawn by us unless otherwise stated. We want to clarify that there is no endorsement of the product implied or inferred. This report is not to be copied or reproduced in whole or in part and cannot be used as evidence in a court of law Legal disputes are subjected to Panchkula jurisdiction only.



Satiate

Research & Anatech Pvt. Ltd.

NABL ACCREDITED GOVT. APPROVED TESTING LABORATORY
 Plot No. 264, 1st & 2nd Floor, HSIIDC, Barwala-134118, Panchkula (Haryana)
 E-mail: satiateresearch@gmail.com, Website : www.sralabs.com



TEST REPORT

FDA Lic. No. : 25-LAB-HR

Form-39A, 150-E (f) Report of test or Analysis by Approved Institution For Procurement Agency

Name of sample	: Prednisolone Tablets IP 10mg	AR No.	: SA/GO-181225/006
Batch No.	: ACT10-239	Batch Size	: NM
D/M	: 09/2025	D/E	: 08/2027
Original Manufacturer	: NM	Name of supplier	: NM
Mfg. Lic. No	: NM	Ref. No.(As in test request slip)	: NM
Sample Submitted By	: Medical Superintendent ESIC	Ref. No.(As given by party)	: NM
Address	: ESIC Pooluvapatti to Thirumurugan Poondi Ring Road Tiruppur - 641 603 Tiruppur - 641	Sample Quantity	: 70 Tablets
Date of receipt	: 17/11/2025	Sample received on	: 18/12/2025
Date of start of analysis	: 18/12/2025	Date of completion of analysis	: 24/12/2025
Protocol of test applied	: IP 2022 & IP Addendum 2024	Date of Issue of the report	: 25/12/2025

TEST PARAMETERS	OBTAINED			LIMITS
Description	: White circular shaped biconvex uncoated tablets plain on both sides.			
Average weight	: 101.67 mg			
Uniformity of weight	: Min	Max		Limit
	-1.25 %	+2.51 %		±7.5 % of average weight
Identification Test	:			
A - By IR	: Complies			To comply
B - By HPLC	: Complies			To comply
Uniformity of content	: Min	Max	Avg	
	96.56 %	101.42 %	99.48 %	
Acceptanc value	: 3.8			NMT 15.0
Dissolution test (By UV)	: Min	Max	Avg	Limit
In water	: 90.48 %	95.56 %	93.42 %	Q.NLT 70.00 %
Related substances (By HPLC)	:			
Any secondary impurity	: 0.12 %			NMT 1.00 %
Sum of all the impurities	: 0.12 %			NMT 3.00 %
Leak test	: Complies			To comply
Hardness	: 2.5 kg/cm ²			
Friability	: 0.11 %			NMT 1.0 %
CONTENTS	OBTAINED			METHOD
Assay (By HPLC) :-				
Composition				
Each uncoated tablet contains :-				
Prednisolone IP	9.95 mg	10.00 mg	(9.00 - 11.00) mg	IP 2022

Disclaimer :

Satiate Research & Anatech Pvt. Ltd. committed to maintain client (s) Privacy and confidentiality at our platform. Please note that the contents of this report and any attached documents are confidential and intended solely for the mentioned client, only. We are excited to share this report with our client and cannot be used in any advertising media without our special permission in writing. Reported results are related only to items tested/requested by client and only to the standards / procedures indicated on the report. Sample is not drawn by us unless otherwise stated. We want to clarify that there is no endorsement of the product implied or inferred. This report is not to be copied or reproduced in whole or in part and cannot be used as evidence in a court of law. Legal disputes are subjected to Panchkula jurisdiction only.



Satiate

Research & Anatech Pvt. Ltd.

NABL ACCREDITED GOVT. APPROVED TESTING LABORATORY
 Plot No. 264, 1st & 2nd Floor, HSIIDC, Barwala-134118, Panchkula (Haryana)
 E-mail: satiate@research@gmail.com, Website : www.sralabs.com



TEST REPORT

FDA Lic. No. : 25-LAB-HR

Form-39A, 150-E (f) Report of test or Analysis by Approved Institution For Procurement Agency

Name of sample	: Prednisolone Tablets IP 10mg	AR No.	: SA/GO-181225/006
Batch No.	: ACT10-239	Batch Size	: NM
D/M	: 09/2025	D/E	: 08/2027
Original Manufacturer	: NM	Name of supplier	: NM
Mfg. Lic. No	: NM	Ref. No.(As in test request slip)	: NM
Sample Submitted By	: Medical Superintendent ESIC	Ref. No.(As given by party)	: NM
Address	: ESIC Pooluvapatti to Thirumurugan Poondi Ring Road Tiruppur - 641 603 Tiruppur - 641	Sample Quantity	: 70 Tablets
Date of receipt	: 17/11/2025	Sample received on	: 18/12/2025
Date of start of analysis	: 18/12/2025	Date of completion of analysis	: 24/12/2025
Protocol of test applied	: IP 2022 & IP Addendum 2024	Date of Issue of the report	: 25/12/2025

In the opinion of the undersigned, the sample referred to above is of Standard Quality as defined in the Drugs and Cosmetics Act and the Rules made under for the reasons given below in respect to Test(s) mentioned above.

End of Report



Date : 25/12/2025

Person In-charge of Testing

Dr Surender Panghal (M.Pharma, Ph.D.)
 (Quality Manager)

Disclaimer :

Satiate Research & Anatech Pvt. Ltd. committed to maintain client (s) Privacy and confidentiality at our platform. Please note that the contents of this report and any attached documents are confidential and intended solely for the mentioned client only. We are excited to share this report with our client and cannot be used in any advertising media without our special permission in writing. Reported results are related only to items tested/requested by client and only to the standards / procedures indicated on the report. Sample is not drawn by us unless otherwise stated. We want to clarify that there is no endorsement of the product implied or inferred. This report is not to be copied or reproduced in whole or in part and cannot be used as evidence in a court of law Legal disputes are subjected to Panchkula jurisdiction only.



Satiate

Research & Anatech Pvt. Ltd.

NABL ACCREDITED GOVT. APPROVED TESTING LABORATORY
 Plot No. 264, 1st & 2nd Floor, HSIIDC, Barwala-134118, Panchkula (Haryana)
 E-mail: satiate.research@gmail.com, Website : www.sralabs.com



TEST REPORT

FDA Lic. No. : 25-LAB-HR

Form-39A, 150-E (f) Report of test or Analysis by Approved Institution For Procurement Agency

Name of sample	: Carboxymethyl Cellulose Sodium Eye Drops	AR No.	: SA/GO-181225/007
	IP 0.5% w/v	Batch Size	: NM
Batch No.	: 1225056	D/E	: 08/2027
D/M	: 09/2025	Name of supplier	: NM
Original Manufacturer	: NM	Ref. No.(As in test request slip)	: NM
Mfg. Lic. No	: NM	Ref. No.(As given by party)	: NM
Sample Submitted By	: Medical Superintendent ESIC	Sample Quantity	: 15 Nos.
Address	: ESIC Pooluvapatti to Thirumurugan Poondi Ring Road Tiruppur - 641 603 Tiruppur - 641	Sample received on	: 18/12/2025
Date of receipt	: 17/11/2025	Date of completion of analysis	: 01/01/2026
Date of start of analysis	: 18/12/2025	Date of Issue of the report	: 01/01/2026
Protocol of test applied	: IP Addendum 2024 & Amendment list 07		

<u>TEST PARAMETERS</u>	<u>OBTAINED</u>	<u>LIMITS</u>
Description	: Clear colourless liquid filled in green coloured plastic vial.	
Identification Test	:	
A- By Chemically	: Complies	To comply
B- By UV	: Complies	To comply
Appearance of solution	:	
i) Clarity of solution	: Complies	To comply
II) Colour of solution	: Complies	To comply
pH	: 7.452	(6.00 - 8.00)
Nominal volume	: 10.0 ml	
Uniformity of filled volume	: Min 10.2 ml Max 10.6 ml	Limit NLT 9.0 ml
Osmolality	: 295.5 mOsmol/L	(270.00 - 350.00) mOsmol/Kg
Sterility	: Complies	To comply
Leak Test	: Complies	To comply
<u>CONTENTS</u>	<u>OBTAINED</u>	<u>CLAIM</u>
Assay :- (By UV)		
Composition		
Carboxymethyl cellulose sodium IP	0.499 % w/v	0.50 % w/v (0.475 - 0.575) % w/v
		<u>METHOD</u>
		IP Addendum 2024/Amendment List-07

Disclaimer :

Satiate Research & Anatech Pvt. Ltd. committed to maintain client (s) Privacy and confidentiality at our platform. Please note that the contents of this report and any attached documents are confidential and intended solely for the mentioned client only. We are excited to share this report with our client and cannot be used in any advertising media without our special permission in writing. Reported results are related only to items tested/requested by client and only to the standards / procedures indicated on the report. Sample is not drawn by us unless otherwise stated. We want to clarify that there is no endorsement of the product implied or inferred. This report is not to be copied or reproduced in whole or in part and cannot be used as evidence in a court of law Legal disputes are subjected to Panchkula jurisdiction only.



Satiate

Research & Anatech Pvt. Ltd.

NABL ACCREDITED GOVT. APPROVED TESTING LABORATORY
 Plot No. 264, 1st & 2nd Floor, HSIIDC, Barwala-134118, Panchkula (Haryana)
 E-mail: satiate.research@gmail.com, Website : www.sralabs.com



TEST REPORT

FDA Lic. No. : 25-LAB-HR

Form-39A, 150-E (f) Report of test or Analysis by Approved Institution For Procurement Agency


Name of sample	: Carboxymethyl Cellulose Sodium Eye Drops	AR No.	: SA/GO-181225/007
	IP 0.5% w/v	Batch Size	: NM
Batch No.	: 1225056	D/E	: 08/2027
D/M	: 09/2025	Name of supplier	: NM
Original Manufacturer	: NM	Ref. No.(As in test request slip)	: NM
Mfg. Lic. No	: NM	Ref. No.(As given by party)	: NM
Sample Submitted By	: Medical Superintendent ESIC	Sample Quantity	: 15 Nos.
Address	: ESIC Pooluvapatti to Thirumurugan Poondi Ring Road Tiruppur - 641 603 Tiruppur - 641	Sample received on	: 18/12/2025
Date of receipt	: 17/11/2025	Date of completion of analysis	: 01/01/2026
Date of start of analysis	: 18/12/2025	Date of Issue of the report	: 01/01/2026
Protocol of test applied	: IP Addendum 2024 & Amendment list 07		

In the opinion of the undersigned, the sample referred to above is of Standard Quality as defined in the Drugs and Cosmetics Act and the Rules made under for the reasons given below in respect to Test(s) mentioned above.

End of Report



Date : 01/01/2026


 Person In-charge of Testing
 Dr. Surender Panghal (M.Pharma, Ph.D.)
 (Quality Manager)

Disclaimer :

Satiate Research & Anatech Pvt. Ltd. committed to maintain client (s) Privacy and confidentiality at our platform. Please note that the contents of this report and any attached documents are confidential and intended solely for the mentioned client only. We are excited to share this report with our client and cannot be used in any advertising media without our special permission in writing. Reported results are related only to items tested/requested by client and only to the standards / procedures indicated on the report. Sample is not drawn by us unless otherwise stated. We want to clarify that there is no endorsement of the product implied or inferred. This report is not to be copied or reproduced in whole or in part and cannot be used as evidence in a court of law Legal disputes are subjected to Panchkula jurisdiction only.



Satiate

Research & Anatech Pvt. Ltd.

NABL ACCREDITED GOVT. APPROVED TESTING LABORATORY
 Plot No. 264, 1st & 2nd Floor, HSIIDC, Barwala-134118, Panchkula (Haryana)
 E-mail: satiate@research@gmail.com, Website : www.sralabs.com



TEST REPORT

FDA Lic. No. : 25-LAB-HR

Form-39A, 150-E (f) Report of test or Analysis by Approved Institution For Procurement Agency

Name of sample	: Spironolactone Tablets IP 25 mg	AR No.	: SA/GO-181225/008
Batch No.	: T250920	Batch Size	: NM
D/M	: 09/2025	D/E	: 08/2027
Original Manufacturer	: NM	Name of supplier	: NM
Mfg. Lic. No	: NM	Ref. No.(As in test request slip)	: NM
Sample Submitted By	: Medical Superintendent ESIC	Ref. No.(As given by party)	: NM
Address	: ESIC Pooluvapatti to Thirumurugan Poondi Ring Road Tiruppur - 641 603 Tiruppur - 641	Sample Quantity	: 70 Tablets
Date of receipt	: 17/11/2025	Sample received on	: 18/12/2025
Date of start of analysis	: 18/12/2025	Date of completion of analysis	: 24/12/2025
Protocol of test applied	: IP 2022	Date of Issue of the report	: 25/12/2025

TEST PARAMETERS	OBTAINED			LIMITS
Description	: White circular shaped flat uncoated tablet having scored line on one side and plain on other side.			
Average weight	: 180.12 mg			
Uniformity of weight	: Min -1.21 %	Max +2.15 %		Limit ±7.5 % of average weight
Identification Test	:			
A-By IR	: Complies			To comply
B-By TLC	: Complies			To comply
C-By Chemical test	: Complies			To comply
Dissolution test (By UV)	: Min 90.18 %	Max 95.36 %	Avg 93.42 %	Limit Q. NLT 70.00 %
Uniformity of content	: 95.27 %	100.32 %	98.29 %	
Acceptance value	: 3.8			NMT 15.0
Related substances (By HPLC)	:			
Sum of all secondary impurities (Other than canrenone)	: 0.12 %			NMT 1.00 %
Canrenone	: 0.15 %			NMT 1.00 %
Total impurities	: 0.27 %			NMT 1.00 %
Leak test	: Complies			To comply
Hardnes	: 3.5 kg/cm ²			
Friability	: 0.15 %			NMT 1.0 %
CONTENTS	OBTAINED	CLAIM	LIMITS	METHOD
Assay (By UV) :-				
Each uncoated tablet contains:-				
Spironolactone IP	24.57 mg	25.00 mg	(23.75 - 26.25) mg	IP 2022

Disclaimer :

Satiate Research & Anatech Pvt. Ltd. committed to maintain client (s) Privacy and confidentiality at our platform. Please note that the contents of this report and any attached documents are confidential and intended solely for the mentioned client only. We are excited to share this report with our client and cannot be used in any advertising media without our special permission in writing. Reported results are related only to items tested/requested by client and only to the standards / procedures indicated on the report. Sample is not drawn by us unless otherwise stated. We want to clarify that there is no endorsement of the product implied or inferred. This report is not to be copied or reproduced in whole or in part and cannot be used as evidence in a court of law Legal disputes are subjected to Panchkula jurisdiction only.



Satiate

Research & Anatech Pvt. Ltd.

NABL ACCREDITED GOVT. APPROVED TESTING LABORATORY
 Plot No. 264, 1st & 2nd Floor, HSIIDC, Barwala-134118, Panchkula (Haryana)
 E-mail: satiate.research@gmail.com, Website : www.sralabs.com



TEST REPORT

FDA Lic. No. : 25-LAB-HR

Form-39A, 150-E (f) Report of test or Analysis by Approved Institution For Procurement Agency

Name of sample	: Spironolactone Tablets IP 25 mg	AR No.	: SA/GO-181225/008
Batch No.	: T250920	Batch Size	: NM
D/M	: 09/2025	D/E	: 08/2027
Original Manufacturer	: NM	Name of supplier	: NM
Mfg. Lic. No	: NM	Ref. No.(As in test request slip)	: NM
Sample Submitted By	: Medical Superintendent ESIC	Ref. No.(As given by party)	: NM
Address	: ESIC Pooluvapatti to Thirumurugan Poondi Ring Road Tiruppur - 641 603 Tiruppur - 641	Sample Quantity	: 70 Tablets
Date of receipt	: 17/11/2025	Sample received on	: 18/12/2025
Date of start of analysis	: 18/12/2025	Date of completion of analysis	: 24/12/2025
Protocol of test applied	: IP 2022	Date of Issue of the report	: 25/12/2025

In the opinion of the undersigned, the sample referred to above is of Standard Quality as defined in the Drugs and Cosmetics Act and the Rules made under for the reasons given below in respect to Test(s) mentioned above.

End of Report



Date : 25/12/2025

Person In-charge of Testing

Dr Surender Panghal (M.Pharma, Ph.D.)
 (Quality Manager)

Disclaimer :

Satiate Research & Anatech Pvt. Ltd. committed to maintain client (s) Privacy and confidentiality at our platform. Please note that, the contents of this report and any attached documents are confidential and intended solely for the mentioned client only. We are excited to share this report with our client and cannot be used in any advertising media without our special permission in writing. Reported results are related only to items tested/requested by client and only to the standards / procedures indicated on the report. Sample is not drawn by us unless otherwise stated. We want to clarify that there is no endorsement of the product implied or inferred. This report is not to be copied or reproduced in whole or in part and cannot be used as evidence in a court of law Legal disputes are subjected to Panchkula jurisdiction only.



Satiate

Research & Anatech Pvt. Ltd.

NABL ACCREDITED GOVT. APPROVED TESTING LABORATORY
 Plot No. 264, 1st & 2nd Floor, HSIIDC, Barwala-134118, Panchkula (Haryana)
 E-mail: satiate@research@gmail.com, Website : www.sralabs.com



TEST REPORT

FDA Lic. No. : 25-LAB-HR

Form-39A, 150-E (f) Report of test or Analysis by Approved Institution For Procurement Agency

Name of sample	: Mupirocin Ointment IP 2 % w/w,	AR No.	: SA/GO-181225/009
Batch No.	: 2501348	Batch Size	: NM
D/M	: 01/2025	D/E	: 12/2027
Original Manufacturer	: NM	Name of supplier	: NM
Mfg. Lic. No	: NM	Ref. No.(As in test request slip)	: NM
Sample Submitted By	: Medical Superintendent ESIC	Ref. No.(As given by party)	: NM
Address	: ESIC Pooluvapatti to Thirumurugan Poondi Ring Road Tiruppur - 641 603 Tiruppur - 641	Sample Quantity	: 12 Nos.
Date of receipt	: 17/11/2025	Sample received on	: 18/12/2025
Date of start of analysis	: 18/12/2025	Date of completion of analysis	: 24/12/2025
Protocol of test applied	: IP 2022	Date of Issue of the report	: 24/12/2025

TEST PARAMETERS	OBTAINED	LIMITS
Description	: Colourless semi solid mass filled in printed laminated tube.	
Nominal weight	: 5.00 g	
Uniformity of fill. weight	: Min. 5.02 g Max 5.12 g	Limit NLT 4.5 g
Identification Test	:	
A-By TLC	: Complies	To comply
B-By HPLC	: Complies	To comply
Related substances (By HPLC)	:	
Mupirocin Impurity C3	: 0.58 %	NMT 4.00 %
Mupirocin Impurity D1	: 0.69 %	NMT 5.00 %
Mupirocin Impurity E2	: 1.65 %	NMT 10.00 %
Any other secondary impurity	: 0.15 %	NMT 1.50 %
Sum of all secondary impurities	: 3.07 %	NMT 20.00 %
CONTENTS	OBTAINED	CLAIM
Assay (By HPLC) :-		
Composition :-		
Mupirocin IP	1.99 % w/w	2.00 % w/w (1.80 - 2.30) % w/w

In the opinion of the undersigned, the sample referred to above is of Standard Quality as defined in the Drugs and Cosmetics Act and the Rules made under for the reasons given below in respect to Test(s) mentioned above.

End of Report



Date : 24/12/2025

Person In-charge of Testing

Dr Surender Panghal (M.Pharma, Ph.D.)
(Quality Manager)

Page : 1 of 1

Disclaimer :

Satiate Research & Anatech Pvt. Ltd. committed to maintain client (s) Privacy and confidentiality at our platform. Please note that the contents of this report and any attached documents are confidential and intended solely for the mentioned client only. We are excited to share this report with our client and cannot be used in any advertising media without our special permission in writing. Reported results are related only to items tested/requested by client and only to the standards / procedures indicated on the report. Sample is not drawn by us unless otherwise stated. We want to clarify that there is no endorsement of the product implied or inferred. This report is not to be copied or reproduced in whole or in part and cannot be used as evidence in a court of law Legal disputes are subjected to Panchkula jurisdiction only.



Satiate

Research & Anatech Pvt. Ltd.

NABL ACCREDITED GOVT. APPROVED TESTING LABORATORY
 Plot No. 264, 1st & 2nd Floor, HSIIDC, Barwala-134118, Panchkula (Haryana)
 E-mail: satiateresearch@gmail.com, Website : www.sralabs.com



TEST REPORT

FDA Lic. No. : 25-LAB-HR

Form-39A, 150-E (f) Report of test or Analysis by Approved Institution For Procurement Agency

Name of sample	: Trypsin and Chymotrypsin (1:6) Tablets 100K	AR No.	: SA/GO-181225/010
Batch No.	Batch Size	: NM	
Batch No.	AU	Batch Size	: NM
D/M	D/E	: 08/2027	
Original Manufacturer	Name of supplier	: NM	
Mfg. Lic. No	Ref. No.(As in test request slip)	: NM	
Sample Submitted By	Ref. No.(As given by party)	: NM	
Address	Sample Quantity	: 80 Tablets	
Date of receipt	Sample received on	: 18/12/2025	
Date of start of analysis	Date of completion of analysis	: 24/12/2025	
Protocol of test applied	Date of Issue of the report	: 25/12/2025	

TEST PARAMETERS	OBTAINED	LIMITS	
Description	: Brick red coloured circular shaped biconvex enteric coated tablet plain surface on both sides.		
Average weight	: 147.12 mg		
Uniformity of weight	: Min Max -1.42 % +2.57 %	Limit ±7.5 % of average weight	
Identification Test (By UV)	: Complies	To comply	
Colour Identification	: Complies	To comply	
Disintegration Time	:	Should not break in 120 Min.	
In 0.1 M HCl acid	: Not break	Should not break in 120 Min.	
In phosphate buffer pH 6.8	: 23 Min 28 Sec.	NMT 60.0 Min.	
Leak test	: Complies	To comply	
Hardness	: 3.5 kg/cm ²		
CONTENTS	OBTAINED	CLAIM	LIMITS
Assay :			
Each enteric coated tablet contains			
100,000 Amour units trypsin	102570.00 IU	100,000.00 IU	NLT 90,000.0 IU
chymotrypsin of enzymatic activity			
Supplied by a purified concentrate			
which has			
Specified trypsin & chymotrypsin			
activity in the ratio of			
Approximately six to one			

Disclaimer :

Satiate Research & Anatech Pvt. Ltd. committed to maintain client (s) Privacy and confidentiality at our platform. Please note that the contents of this report and any attached documents are confidential and intended solely for the mentioned client only. We are excited to share this report with our client and cannot be used in any advertising media without our special permission in writing. Reported results are related only to items tested/requested by client and only to the standards / procedures indicated on the report. Sample is not drawn by us unless otherwise stated. We want to clarify that there is no endorsement of the product implied or inferred. This report is not to be copied or reproduced in whole or in part and cannot be used as evidence in a court of law. Legal disputes are subjected to Panchkula jurisdiction only.



Satiate

Research & Anatech Pvt. Ltd.

NABL ACCREDITED GOVT. APPROVED TESTING LABORATORY
 Plot No. 264, 1st & 2nd Floor, HSIIDC, Barwala-134118, Panchkula (Haryana)
 E-mail: satiate.research@gmail.com, Website : www.sralabs.com



TEST REPORT

FDA Lic. No. : 25-LAB-HR

Form-39A, 150-E (f) Report of test or Analysis by Approved Institution For Procurement Agency


Name of sample	: Trypsin and Chymotrypsin (1:6) Tablets 100K	AR No.	: SA/GO-181225/010
	AU	Batch Size	: NM
Batch No.	: GAET25010	D/E	: 08/2027
D/M	: 09/2025	Name of supplier	: NM
Original Manufacturer	: NM	Ref. No.(As in test request slip)	: NM
Mfg. Lic. No	: NM	Ref. No.(As given by party)	: NM
Sample Submitted By	: Medical Superintendent ESIC	Sample Quantity	: 80 Tablets
Address	: ESIC Pooluvapatti to Thirumurugan Poondi Ring Road Tiruppur - 641 603 Tiruppur - 641	Sample received on	: 18/12/2025
Date of receipt	: 17/11/2025	Date of completion of analysis	: 24/12/2025
Date of start of analysis	: 20/12/2025	Date of Issue of the report	: 25/12/2025
Protocol of test applied	: As per manufacturer's specification.		

In the opinion of the undersigned, the sample referred to above is of Standard Quality as defined in the Drugs and Cosmetics Act and the Rules made under for the reasons given below in respect to Test(s) mentioned above.

End of Report




Date : 25/12/2025


 Person In-charge of Testing
 Dr Surender Panghal (M.Pharma, Ph.D.)
 (Quality Manager)

Disclaimer :

Satiate Research & Anatech Pvt. Ltd. committed to maintain client (s) Privacy and confidentiality at our platform. Please note that the contents of this report and any attached documents are confidential and intended solely for the mentioned client only. We are excited to share this report with our client and cannot be used in any advertising media without our special permission in writing. Reported results are related only to items tested/requested by client and only to the standards / procedures indicated on the report. Sample is not drawn by us unless otherwise stated. We want to clarify that there is no endorsement of the product implied or inferred. This report is not to be copied or reproduced in whole or in part and cannot be used as evidence in a court of law Legal disputes are subjected to Panchkula jurisdiction only.



Satiate

Research & Anatech Pvt. Ltd.

NABL ACCREDITED GOVT. APPROVED TESTING LABORATORY
 Plot No. 264, 1st & 2nd Floor, HSIIDC, Barwala-134118, Panchkula (Haryana)
 E-mail: satiateresearch@gmail.com, Website : www.sralabs.com

TEST REPORT



FDA Lic. No. : 25-LAB-HR

Form-39A, 150-E (f) Report of test or Analysis by Approved Institution For Procurement Agency

Name of sample	: Methylcobalamin Injection 500mcg	AR No.	: SA/GO-181225/011
Batch No.	: D31Y017	Batch Size	: NM
D/M	: 07/2025	D/E	: 06/2027
Original Manufacturer	: NM	Name of supplier	: NM
Mfg. Lic. No	: NM	Ref. No.(As in test request slip)	: NM
Sample Submitted By	: Medical Superintendent ESIC	Ref. No.(As given by party)	: NM
Address	: ESIC Pooluvapatti to Thirumurugan Poondi Ring Road Tiruppur - 641 603	Sample Quantity	: 30 Nos.
Date of receipt	: 17/11/2025	Sample received on	: 18/12/2025
Date of start of analysis	: 18/12/2025	Date of completion of analysis	: 01/01/2026
Protocol of test applied	: As per manufacturer's specification.	Date of Issue of the report	: 02/01/2026

<u>TEST PARAMETERS</u>	<u>OBTAINED</u>	<u>LIMITS</u>
Description	: Red coloured liquid filled in amber coloured glass ampoule.	
Identification test	: Complies	To comply
pH	: 4.751	
Nominal volume	: 1.0 ml	
Extractable volume	: 1.1 ml	NLT 1.0 ml
Particulate Matter	:	
Greater than or Equal to 10 μ m	: 265 Particles/Container	NMT 6000 Particles/Container
Greater than or Equal to 25 μ m	: 55 Particles/Container	NMT 600 Particles/Container
Sterility	: Complies	To comply
Leak Test	: Complies	To comply
<u>CONTENTS</u>	<u>OBTAINED</u>	<u>CLAIM</u>
Assay		
Composition		
Each ml contains		
Methylcobalamin IP	512.25 mcg	(450.00 - 550.00) mcg

Note:- 1.The result listed refers only to the tested samples & applicable parameters; endorsement of products is neither inferred nor implied.

2.Total liability of our institute is limited to the invoiced amount

3.This report is not to be reproduced wholly or in part and cannot be used as evidence in the court of law and should not be used in any advertising media without our special permission in writing.

4.Sample drawn and submitted by the party for Analysis unless otherwise stated.

5.Party has asked for the above tests only.

Page : 1 of 2

Disclaimer :

Satiate Research & Anatech Pvt. Ltd. committed to maintain client (s) Privacy and confidentiality at our platform. Please note that the contents of this report and any attached documents are confidential and intended solely for the mentioned client only. We are excited to share this report with our client and cannot be used in any advertising media without our special permission in writing. Reported results are related only to items tested/requested by client and only to the standards / procedures indicated on the report. Sample is not drawn by us unless otherwise stated. We want to clarify that there is no endorsement of the product implied or inferred. This report is not to be copied or reproduced in whole or in part and cannot be used as evidence in a court of law Legal disputes are subjected to Panchkula jurisdiction only.



Satiate

Research & Anatech Pvt. Ltd.

NABL-ACCREDITED GOVT. APPROVED TESTING LABORATORY
 Plot No. 264, 1st & 2nd Floor, HSIIDC, Barwala-134118, Panchkula (Haryana)
 E-mail: satiate.research@gmail.com, Website : www.sralabs.com

TEST REPORT



FDA Lic. No. : 25-LAB-HR

Form-39A, 150-E (f) Report of test or Analysis by Approved Institution For Procurement Agency

Name of sample	: Methylcobalamin Injection 500mcg	AR No.	: SA/GO-181225/011
Batch No.	: D31Y017	Batch Size	: NM
D/M	: 07/2025	D/E	: 06/2027
Original Manufacturer	: NM	Name of supplier	: NM
Mfg. Lic. No	: NM	Ref. No.(As in test request slip)	: NM
Sample Submitted By	: Medical Superintendent ESIC	Ref. No.(As given by party)	: NM
Address	: ESIC Pooluvapatti to Thirumurugan Poondi Ring Road Tiruppur - 641 603	Sample Quantity	: 30 Nos.
Date of receipt	: 17/11/2025	Sample received on	: 18/12/2025
Date of start of analysis	: 18/12/2025	Date of completion of analysis	: 01/01/2026
Protocol of test applied	: As per manufacturer's specification.	Date of Issue of the report	: 02/01/2026

In the opinion of the undersigned, the sample referred to above is of Standard Quality as defined in the Drugs and Cosmetics Act and the Rules made under for the reasons given below in respect to Test(s) mentioned above.

End of Report



Date : 02/01/2026

Person In-charge of Testing

Dr Surender Panghal (M.Pharma, Ph.D.)
 (Quality Manager)

Note:-

- 1.The result listed refers only to the tested samples & applicable parameters; endorsement of products is neither inferred nor implied.
- 2.Total liability of our institute is limited to the invoiced amount
- 3.This report is not to be reproduced wholly or in part and cannot be used as evidence in the court of law and should not be used in any advertising media without our special permission in writing.
- 4.Sample drawn and submitted by the party for Analysis unless otherwise stated.
- 5.Party has asked for the above tests only.

Page : 2 of 2

Disclaimer :

Satiate Research & Anatech Pvt. Ltd. committed to maintain client (s) Privacy and confidentiality at our platform. Please note that the contents of this report and any attached documents are confidential and intended solely for the mentioned client only. We are excited to share this report with our client and cannot be used in any advertising media without our special permission in writing. Reported results are related only to items tested/requested by client and only to the standards / procedures indicated on the report. Sample is not drawn by us unless otherwise stated. We want to clarify that there is no endorsement of the product implied or inferred. This report is not to be copied or reproduced in whole or in part and cannot be used as evidence in a court of law Legal disputes are subjected to Panchkula jurisdiction only.



Satiate

Research & Anatech Pvt. Ltd.

NABL ACCREDITED GOVT. APPROVED TESTING LABORATORY
 Plot No. 264, 1st & 2nd Floor, HSIIDC, Barwala-134118, Panchkula (Haryana)
 E-mail: satiate.research@gmail.com, Website : www.sralabs.com

TEST REPORT

FDA Lic. No. : 25-LAB-HR

Form-39A, 150-E (f) Report of test or Analysis by Approved Institution For Procurement Agency

Name of Sample	: Diclofenac Diethylamine 1.16 % w/w, Linseed Oil 3%, w/w Methyl Salicylate 10 % w/w and Menthol 5 % w/w Spray	AR. No.	: SA/GO-181225/012
Batch No.	: W250120	Batch size	: NM
D/M	: 08/2025	D/E	: 07/2028
Original Manufacturer	: NM	Name of supplier	: NM
Mfg. Lic. No	: NM	Ref. No. (As in test req. Slip)	: NM
Sample Submitted By	: Medical Superintendent ESIC	Ref. No. (As given by party)	: NM
Address	: ESIC Pooluvapatti to Thirumurugan Poondi Ring Road Tiruppur-641603	Sample quantity	: 03 Nos.
Date of receipt	: 17/11/2025	Sample received on	: 18/12/2025
Date of start analysis	: 18/12/2025	Date of completion of analysis	: 21/12/2025
Protocol of test applied	: As per manufacturer's specification.	Date of Issue of the report	: 23/12/2025

Description	Colourless liquid filled in printed aluminium container.		
Identification Test (By HPLC)			
A- Diclofenac Diethylamine	Complies	To comply	
B- Menthol & Methyl Salicylate	Complies	To comply	
C- Linseed Oil	Complies	To comply	
Nominal weight	142.00 g		
Extractable weight	142.5 g	NLT 142.00 g	
Can pressure @ 25°C	39.12 pSi°	NLT 35 pSi°	
Delivery rate @ 25°C	0.870 g/sec.	(0.300 – 1.500) g/sec	
Leak test	Complies	To comply	


<u>TEST PARAMETERS</u>	<u>RESULT</u>	<u>CLAIM</u>	<u>LIMIT</u>
Assay:-			
Composition			
Diclofenac Diethylamine IP (1.16 % w/w)			
Eq. to Diclofenac Sodium IP	0.987 % w/w	1.00 % w/w	(0.90 – 1.100) % w/w
Virgin Linseed Oil BP	2.98 % w/w	3.00 % w/w	(2.70 – 3.30) % w/w
Methyl Salicylate IP	9.89 % w/w	10.00 % w/w	(9.00 – 11.00) % w/w
Menthol IP	4.97 % w/w	5.00 % w/w	(4.50 – 6.00) % w/w

In the opinion of the undersigned, the sample referred to above is of Standard Quality as defined in the Drugs and Cosmetics Act and the Rules made under for the reasons given below in respect to Test(s) mentioned above.

End of Report



Date : 23/12/2025


 Person-in charge of testing
 Dr. Surender Panghal (M. Pharma, Ph.D.)
 (Quality Manager)

Disclaimer :

Satiate Research & Anatech Pvt. Ltd. committed to maintain client (s) Privacy and confidentiality at our platform. Please note that the contents of this report and any attached documents are confidential and intended solely for the mentioned client only. We are excited to share this report with our client and cannot be used in any advertising media without our special permission in writing. Reported results are related only to items tested/requested by client and only to the standards / procedures indicated on the report. Sample is not drawn by us unless otherwise stated. We want to clarify that there is no endorsement of the product implied or inferred. This report is not to be copied or reproduced in whole or in part and cannot be used as evidence in a court of law. Legal disputes are subjected to Panchkula jurisdiction only.



Satiate

Research & Anatech Pvt. Ltd.

NABL ACCREDITED GOVT. APPROVED TESTING LABORATORY
 Plot No. 264, 1st & 2nd Floor, HSIIDC, Barwala-134118, Panchkula (Haryana)
 E-mail: satiate.research@gmail.com, Website : www.sralabs.com



TEST REPORT

FDA Lic. No. : 25-LAB-HR

Form-39A, 150-E (f) Report of test or Analysis by Approved Institution For Procurement Agency

Name of sample	: Cilnidipine Tablets IP 10 mg	AR No.	: SA/GO-181225/013
Batch No.	: WCB25012G	Batch Size	: NM
D/M	: 07/2025	D/E	: 06/2027
Original Manufacturer	: NM	Name of supplier	: NM
Mfg. Lic. No	: NM	Ref. No.(As in test request slip)	: NM
Sample Submitted By	: Medical Superintendent ESIC	Ref. No.(As given by party)	: NM
Address	: ESIC Pooluvapatti to Thirumurugan Poondi Ring Road Tiruppur - 641 603 Tiruppur - 641	Sample Quantity	: 70 Tablets
Date of receipt	: 17/11/2025	Sample received on	: 18/12/2025
Date of start of analysis	: 18/12/2025	Date of completion of analysis	: 24/12/2025
Protocol of test applied	: IP 2022	Date of Issue of the report	: 25/12/2025

TEST PARAMETERS	OBTAINED			LIMITS
Description	: White circular shaped biconvex film coated tablet plain surface on both sides.			
Average weight	: 136.95 mg			
Uniformity of weight	: Min	Max		Limit
	-1.32 %	+2.51 %		± 7.5 % of average weight
Identification Test (By HPLC)	: Complies			To comply
Dissolution Test (By UV)	: Min	Max	Avg	Limit
	90.56 %	95.88 %	93.82 %	Q. NLT 70.00 %
Uniformity of content	: 96.52 %	101.56 %	99.48 %	
Acceptance value	: 3.9			NMT 15.0
Related Substances (By HPLC)	:			
Any secondary impurity	: Not detected			NMT 0.5 %
Sum of all secondary impurities	: Not detected			NMT 1.0 %
Leak Test	: Complies			To comply
Hardness	: 2.5 kg/cm ²			
CONTENTS	OBTAINED		CLAIM	LIMITS
Assay (By HPLC)	:			
Composition				
Each film coated tablet contains				
Cilnidipine IP	9.95 mg		10.00 mg	(9.00 - 11.00) mg
				IP 2022

Disclaimer :

Satiate Research & Anatech Pvt. Ltd. committed to maintain client (s) Privacy and confidentiality at our platform. Please note that the contents of this report and any attached documents are confidential and intended solely for the mentioned client only. We are excited to share this report with our client and cannot be used in any advertising media without our special permission in writing. Reported results are related only to items tested/requested by client and only to the standards / procedures indicated on the report. Sample is not drawn by us unless otherwise stated. We want to clarify that there is no endorsement of the product implied or inferred. This report is not to be copied or reproduced in whole or in part and cannot be used as evidence in a court of law. Legal disputes are subjected to Panchkula jurisdiction only.



Satiate

Research & Anatech Pvt. Ltd.

NABL ACCREDITED GOVT. APPROVED TESTING LABORATORY
 Plot No. 264, 1st & 2nd Floor, HSIIDC, Barwala-134118, Panchkula (Haryana)
 E-mail: satiateresearch@gmail.com, Website : www.sralabs.com



TEST REPORT

FDA Lic. No. : 25-LAB-HR

Form-39A, 150-E (f) Report of test or Analysis by Approved Institution For Procurement Agency

Name of sample	: Cilnidipine Tablets IP 10 mg	AR No.	: SA/GO-181225/013
Batch No.	: WCB25012G	Batch Size	: NM
D/M	: 07/2025	D/E	: 06/2027
Original Manufacturer	: NM	Name of supplier	: NM
Mfg. Lic. No	: NM	Ref. No.(As in test request slip)	: NM
Sample Submitted By	: Medical Superintendent ESIC	Ref. No.(As given by party)	: NM
Address	: ESIC Pooluvapatti to Thirumurugan Poondi Ring Road Tiruppur - 641 603 Tiruppur - 641	Sample Quantity	: 70 Tablets
Date of receipt	: 17/11/2025	Sample received on	: 18/12/2025
Date of start of analysis	: 18/12/2025	Date of completion of analysis	: 24/12/2025
Protocol of test applied	: IP 2022	Date of Issue of the report	: 25/12/2025

In the opinion of the undersigned, the sample referred to above is of Standard Quality as defined in the Drugs and Cosmetics Act and the Rules made under for the reasons given below in respect to Test(s) mentioned above.

End of Report

Person In-charge of Testing

Dr Surender Panghal (M.Pharma, Ph.D.)
 (Quality Manager)

Date : 25/12/2025



Disclaimer :

Satiate Research & Anatech Pvt. Ltd. committed to maintain client (s) Privacy and confidentiality at our platform. Please note that the contents of this report and any attached documents are confidential and intended solely for the mentioned client only. We are excited to share this report with our client and cannot be used in any advertising media without our special permission in writing. Reported results are related only to items tested/requested by client and only to the standards / procedures indicated on the report. Sample is not drawn by us unless otherwise stated. We want to clarify that there is no endorsement of the product implied or inferred. This report is not to be copied or reproduced in whole or in part and cannot be used as evidence in a court of law. Legal disputes are subjected to Panchkula jurisdiction only.



Satiate

Research & Anatech Pvt. Ltd.

NABL ACCREDITED GOVT. APPROVED TESTING LABORATORY
 Plot No. 264, 1st & 2nd Floor, HSIIDC, Barwala-134118, Panchkula (Haryana)
 E-mail: satiate@research@gmail.com, Website : www.sralabs.com



TEST REPORT

FDA Lic. No. : 25-LAB-HR

Form-39A, 150-E (f) Report of test or Analysis by Approved Institution For Procurement Agency

Name of sample	: Paracetamol 162.5mg and Tramadol 18.75mg AR No.	: SA/GO-181225/014
	Tablet	Batch Size
Batch No.	: AR2TF01	D/E
D/M	: 08/2025	Name of supplier
Original Manufacturer	: NM	
Mfg. Lic. No	: NM	Ref. No.(As in test request slip)
Sample Submitted By	: Medical Superintendent ESIC	Ref. No.(As given by party)
Address	: ESIC Pooluvapatti to Thirumurugan Poondi Ring Road Tiruppur - 641 603 Tiruppur - 641	Sample Quantity
Date of receipt	: 17/11/2025	Sample received on
Date of start of analysis	: 18/12/2025	Date of completion of analysis
Protocol of test applied	: IP Addendum 2024	Date of Issue of the report

<u>TEST PARAMETERS</u>	<u>OBTAINED</u>			<u>LIMITS</u>
Description	: White circular shaped biconvex film coated tablet plain surface on both sides.			To comply
Identification Test (By HPLC)	: Complies			
Average weight	: 258.17 mg			Limit
Uniformity of weight	: Min Max -1.25 % +2.61 %			±5.0 % of average weight
Dissolution Test (By HPLC)	: Min Max Avg			Limit
0.1 M HCl Acid	:			Q. NLT 80.00 %
For Paracetamol	: 90.56 % 95.42 % 93.65 %			Q. NLT 80.00 %
For Tramadol HCl	: 91.42 % 96.66 % 94.72 %			NMT 0.15 %
4-Aminophenol (By HPLC)	: Not detected			
Related substances (By HPLC)	:			NMT 0.2 %
O -Desmethyl - tramadol	: Not detected			NMT 0.2 %
Tramadol compound A	: Not detected			NMT 0.2 %
Any other secondary impurities	: Not detected			NMT 0.8 %
Sum of all secondary impurities	: Not detected			
Uniformity of content	: Min Max Avg			
For-Tramadol	: 96.56 % 101.48 % 99.58 %			NMT 15.0
Acceptance value	: 3.8			To comply
Leak test	: Complies			
Hardness	: 3.5 kg/cm ²			
<u>CONTENTS</u>		<u>OBTAINED</u>	<u>CLAIM</u>	<u>LIMITS</u>
Assay (By HPLC)				
Each film coated tablet contains				
Paracetamol IP	160.16 mg	162.50 mg	(146.25 - 178.75) mg	IP Addendum

Disclaimer :

Satiate Research & Anatech Pvt. Ltd. committed to maintain client (s) Privacy and confidentiality at our platform. Please note that the contents of this report and any attached documents are confidential and intended solely for the mentioned client only. We are excited to share this report with our client and cannot be used in any advertising media without our special permission in writing. Reported results are related only to items tested/requested by client and only to the standards / procedures indicated on the report. Sample is not drawn by us unless otherwise stated. We want to clarify that there is no endorsement of the product implied or inferred. This report is not to be copied or reproduced in whole or in part and cannot be used as evidence in a court of law Legal disputes are subjected to Panchkula jurisdiction only.



Satiate

Research & Anatech Pvt. Ltd.

NABL ACCREDITED GOVT. APPROVED TESTING LABORATORY
 Plot No. 264, 1st & 2nd Floor, HSIIDC, Baiwala-134118, Panchkula (Haryana)
 E-mail: satiate.research@gmail.com, Website : www.sralabs.com



TEST REPORT

FDA Lic. No. : 25-LAB-HR

Form-39A, 150-E (f) Report of test or Analysis by Approved Institution For Procurement Agency

Name of sample	: Paracetamol 162.5mg and Tramadol 18.75mg	AR No.	: SA/GO-181225/014
Batch No.	Tablet	Batch Size	: NM
D/M	: AR2TF01	D/E	: 07/2027
Original Manufacturer	: 08/2025	Name of supplier	: NM
Mfg. Lic. No	: NM	Ref. No.(As in test request slip)	: NM
Sample Submitted By	: Medical Superintendent ESIC	Ref. No.(As given by party)	: NM
Address	: ESIC Pooluvapatti to Thirumurugan Poondi Ring Road Tiruppur - 641 603 Tiruppur - 641	Sample Quantity	: 70 Tablets
Date of receipt	: 17/11/2025	Sample received on	: 18/12/2025
Date of start of analysis	: 18/12/2025	Date of completion of analysis	: 24/12/2025
Protocol of test applied	: IP Addendum 2024	Date of Issue of the report	: 25/12/2025


CONTENTS	OBTAINED	CLAIM	LIMITS	METHOD
Tramadol HCl IP	18.67 mg	18.75 mg	(16.88 - 20.63) mg	IP Addendum 2024

In the opinion of the undersigned, the sample referred to above is of Standard Quality as defined in the Drugs and Cosmetics Act and the Rules made under for the reasons given below in respect to Test(s) mentioned above.

End of Report



Date : 25/12/2025


 Person In-charge of Testing
 Dr. Surender Panghal (M.Pharma, Ph.D.)
 (Quality Manager)

Disclaimer :

Satiate Research & Anatech Pvt. Ltd. committed to maintain client (s) Privacy and confidentiality at our platform. Please note that the contents of this report and any attached documents are confidential and intended solely for the mentioned client only. We are excited to share this report with our client and cannot be used in any advertising media without our special permission in writing. Reported results are related only to items tested/requested by client and only to the standards / procedures indicated on the report. Sample is not drawn by us unless otherwise stated. We want to clarify that there is no endorsement of the product implied or inferred. This report is not to be copied or reproduced in whole or in part and cannot be used as evidence in a court of law Legal disputes are subjected to Panchkula jurisdiction only.



Satiate

Research & Anatech Pvt. Ltd.

NABL ACCREDITED GOVT. APPROVED TESTING LABORATORY
 Plot No. 264, 1st & 2nd Floor, HSIIDC, Barwala-134118, Panchkula (Haryana)
 E-mail: satiateresearch@gmail.com, Website : www.sralabs.com



TEST REPORT

FDA Lic. No. : 25-LAB-HR

Form-39A, 150-E (f) Report of test or Analysis by Approved Institution For Procurement Agency

Name of sample	: Iron sucrose injection USP	AR No.	: SA/GO-181225/015
Batch No.	: MPJ253642	Batch Size	: NM
D/M	: 09/2025	D/E	: 08/2027
Original Manufacturer	: NM	Name of supplier	: NM
Mfg. Lic. No	: NM	Ref. No.(As in test request slip)	: NM
Sample Submitted By	: Medical Superintendent ESIC	Ref. No.(As given by party)	: NM
Address	: ESIC Pooluvapatti to Thirumurugan Poondi Ring Road Tiruppur - 641 603 Tiruppur - 641	Sample Quantity	: 30 Nos.
Date of receipt	: 17/11/2025	Sample received on	: 18/12/2025
Date of start of analysis	: 18/12/2025	Date of completion of analysis	: 01/01/2026
Protocol of test applied	: USP	Date of Issue of the report	: 01/01/2026

TEST PARAMETERS	OBTAINED	LIMITS
Description	: Brown coloured liquid filled in amber coloured glass ampoule.	
Identification Test	:	
Identification A -Iron	: Complies	
Identification B -Sucrose	: Complies	
Identification C	:	
Molecular weight Determination (MW/MN)	:	
MW	: 47113.46 Da	(34000 - 60000) Da
MN	: 36241.12 Da	NLT 24000 Da
MW/MN	: 1.3	NMT 1.7
Nominal Volume	: 5.0 ml	
Extractable Volume	: 5.2 ml	NLT 5.0 ml
Specific gravity	: 1.152	(1.135 - 1.165)
pH	: 10.942	(10.5 - 11.1)
Absence of low molecular weight	:	
Iron [Fe(II) & FE(III)] Complex	: Complies	To comply (4.4 -5.3)
Turbidity	: 4.9	
Osmolarity	: 1252.45 mOsmol/L	(1150.0 - 1350.0) mOsmol/L
Alkalinity	: 0.6 ml of 0.1 N hydrochloric acid was consumed.	(0.5 - 0.8) ml of 0.1 N hydrochloric acid be consumed per ml of injection
Particulate matter	:	
Greater than or equal to 10 μ m	: 255 Particles/Container	NMT 6000 Particles/Container
Greater than or equal to 25 μ m	: 85 Particles/Container	NMT 600 Particles/Container
Limit of iron FE(II)]	: 0.12 %	NMT 0.40 %

Page : 1 of 2

Disclaimer :

Satiate Research & Anatech Pvt. Ltd. committed to maintain client (s) Privacy and confidentiality at our platform. Please note that the contents of this report and any attached documents are confidential and intended solely for the mentioned client only. We are excited to share this report with our client and cannot be used in any advertising media without our special permission in writing. Reported results are related only to items tested/requested by client and only to the standards / procedures indicated on the report. Sample is not drawn by us unless otherwise stated. We want to clarify that there is no endorsement of the product implied or inferred. This report is not to be copied or reproduced in whole or in part and cannot be used as evidence in a court of law Legal disputes are subjected to Panchkula jurisdiction only.



Satiate

Research & Anatech Pvt. Ltd.

NABL ACCREDITED GOVT. APPROVED TESTING LABORATORY
 Plot No. 264, 1st & 2nd Floor, HSIIDC, Barwala-134118, Panchkula (Haryana)
 E-mail: satiateresearch@gmail.com, Website : www.sralabs.com



TEST REPORT

FDA Lic. No. : 25-LAB-HR


Form-39A, 150-E (f) Report of test or Analysis by Approved Institution For Procurement Agency

Name of sample	: Iron sucrose injection USP	AR No.	: SA/GO-181225/015
Batch No.	: MPJ253642	Batch Size	: NM
D/M	: 09/2025	D/E	: 08/2027
Original Manufacturer	: NM	Name of supplier	: NM
Mfg. Lic. No	: NM	Ref. No.(As in test request slip)	: NM
Sample Submitted By	: Medical Superintendent ESIC	Ref. No.(As given by party)	: NM
Address	: ESIC Pooluvapatti to Thirumurugan Poondi Ring Road Tiruppur - 641 603 Tiruppur - 641	Sample Quantity	: 30 Nos.
Date of receipt	: 17/11/2025	Sample received on	: 18/12/2025
Date of start of analysis	: 18/12/2025	Date of completion of analysis	: 01/01/2026
Protocol of test applied	: USP	Date of Issue of the report	: 01/01/2026

<u>TEST PARAMETERS</u>	<u>OBTAINED</u>	<u>LIMITS</u>	
Description	: Brown coloured liquid filled in amber coloured glass ampoule.		
Content of chloride	: 0.015 %	(0.012 - 0.025) %	
Bacterial Endotoxins	: Less than 3.7 USP EU/mg	NMT 3.7 USP EU/mg	
Sterility	: Complies	To comply	
Sucrose (By AAS)	: 301.41 mg/ml	(260 - 340) mg/ml	
Leak test	: Complies	To comply	
<u>CONTENTS</u>	<u>OBTAINED</u>	<u>CLAIM</u>	<u>LIMITS</u>
Assay:-			
Composition			
Ferric hydroxide in complex with sucrose			
eq. to elemental iron	20.31 mg	20.00 mg	(19.00 - 21.00) mg

In the opinion of the undersigned, the sample referred to above is of Standard Quality as defined in the Drugs and Cosmetics Act and the Rules made under for the reasons given below in respect to Test(s) mentioned above.

End of Report


 Person In-charge of Testing
 Dr Surender Panghal (M.Pharma, Ph.D.)
 (Quality Manager)



Date : 01/01/2026

Disclaimer :

Satiate Research & Anatech Pvt. Ltd. committed to maintain client (s) Privacy and confidentiality at our platform. Please note that the contents of this report and any attached documents are confidential and intended solely for the mentioned client only. We are excited to share this report with our client and cannot be used in any advertising media without our special permission in writing. Reported results are related only to items tested/requested by client and only to the standards / procedures indicated on the report. Sample is not drawn by us unless otherwise stated. We want to clarify that there is no endorsement of the product implied or inferred. This report is not to be copied or reproduced in whole or in part and cannot be used as evidence in a court of law. Legal disputes are subjected to Panchkula jurisdiction only.



Satiate

Research & Anatech Pvt. Ltd.

NABL ACCREDITED GOVT. APPROVED TESTING LABORATORY
 Plot No. 264, 1st & 2nd Floor, HSIIDC, Barwala-134118, Panchkula (Haryana)
 E-mail: satiate@research@gmail.com, Website : www.sralabs.com



TEST REPORT

FDA Lic. No. : 25-LAB-HR

Form-39A, 150-E (f) Report of test or Analysis by Approved Institution For Procurement Agency

Name of sample	: Glimepiride Tablets IP 1 mg	AR No.	: SA/GO-181225/016
Batch No.	: 0065	Batch Size	: NM
D/M	: 09/2025	D/E	: 08/2027
Original Manufacturer	: NM	Name of supplier	: NM
Mfg. Lic. No	: NM	Ref. No.(As in test request slip)	: NM
Sample Submitted By	: Medical Superintendent ESIC	Ref. No.(As given by party)	: NM
Address	: ESIC Pooluvapatti to Thirumurugan Poondi Ring Road Tiruppur - 641 603 Tiruppur - 641	Sample Quantity	: 70 Tablets
Date of receipt	: 17/11/2025	Sample received on	: 18/12/2025
Date of start of analysis	: 20/12/2025	Date of completion of analysis	: 25/12/2025
Protocol of test applied	: IP 2022	Date of Issue of the report	: 26/12/2025

<u>TEST PARAMETERS</u>	<u>OBTAINED</u>	<u>LIMITS</u>
Description	: Light yellow coloured circular shaped biconvex uncoated tablet plain surface on both sides.	
Average weight	: 167.15 mg	
Uniformity of weight	: Min Max -1.26 % +2.63 %	Limit ±7.5 % of average weight
Identification Test (By HPLC)	: Complies	To comply
Leak Test	: Complies	To comply
Hardness	: 3.5 kg/cm ²	
Friability	: 0.12 %	NMT 0.1 %
Related substances (By HPLC)	:	
Glimepiride impurity B	: 0.26 %	NMT 2.50 %
Any other secondary impurity	: Not detected	NMT 0.50 %
Sum of all secondary impurities (Other than impurity B)	: 0.12 %	NMT 1.00 %
Sum of all secondary impurities	: 0.38 %	NMT 3.50 %
Dissolution test (By HPLC)	: Min Max Avg	Limit
In Phosphate buffer (pH 7.8)	: 89.32 % 94.46 % 92.87 %	Q. NLT 75.00 %
Uniformity of content (By HPLC)	: 96.82 % 101.63 % 99.17 %	
Acceptance value	: 3.5	NMT 15.0
<u>CONTENTS</u>	<u>OBTAINED</u>	<u>CLAIM</u>
Assay (By HPLC) :-		<u>LIMITS</u>
Composition		<u>METHOD</u>
Each uncoated tablet contains :-		
Glimepiride IP	0.992 mg	1.00 mg
		(0.90 - 1.10) mg
		IP 2022

Disclaimer :

Satiate Research & Anatech Pvt. Ltd. committed to maintain client (s) Privacy and confidentiality at our platform. Please note that the contents of this report and any attached documents are confidential and intended solely for the mentioned client only. We are excited to share this report with our client and cannot be used in any advertising media without our special permission in writing. Reported results are related only to items tested/requested by client and only to the standards / procedures indicated on the report. Sample is not drawn by us unless otherwise stated. We want to clarify that there is no endorsement of the product implied or inferred. This report is not to be copied or reproduced in whole or in part and cannot be used as evidence in a court of law Legal disputes are subjected to Panchkula jurisdiction only.



Satiate

Research & Anatech Pvt. Ltd.

NABL ACCREDITED GOVT. APPROVED TESTING LABORATORY
 Plot No. 264, 1st & 2nd Floor, HSIIDC, Barwala-134118, Panchkula (Haryana)
 E-mail: satiate.research@gmail.com, Website : www.srlabs.com



TEST REPORT

FDA Lic. No. : 25-LAB-HR

Form-39A, 150-E (f) Report of test or Analysis by Approved Institution For Procurement Agency


Name of sample	: Glimepiride Tablets IP 1 mg	AR No.	: SA/GO-181225/016
Batch No.	: 0065	Batch Size	: NM
D/M	: 09/2025	D/E	: 08/2027
Original Manufacturer	: NM	Name of supplier	: NM
Mfg. Lic. No	: NM	Ref. No.(As in test request slip)	: NM
Sample Submitted By	: Medical Superintendent ESIC	Ref. No.(As given by party)	: NM
Address	: ESIC Pooluvapatti to Thirumurugan Poondi Ring Road Tiruppur - 641 603 Tiruppur - 641	Sample Quantity	: 70 Tablets
Date of receipt	: 17/11/2025	Sample received on	: 18/12/2025
Date of start of analysis	: 20/12/2025	Date of completion of analysis	: 25/12/2025
Protocol of test applied	: IP 2022	Date of Issue of the report	: 26/12/2025

In the opinion of the undersigned, the sample referred to above is of Standard Quality as defined in the Drugs and Cosmetics Act and the Rules made under for the reasons given below in respect to Test(s) mentioned above.

End of Report



Date : 26/12/2025


 Person In-charge of Testing
 Dr Surender Panghal (M.Pharma, Ph.D.)
 (Quality Manager)

Disclaimer :

Satiate Research & Anatech Pvt. Ltd. committed to maintain client (s) Privacy and confidentiality at our platform. Please note that the contents of this report and any attached documents are confidential and intended solely for the mentioned client only. We are excited to share this report with our client and cannot be used in any advertising media without our special permission in writing. Reported results are related only to items tested/requested by client and only to the standards / procedures indicated on the report. Sample is not drawn by us unless otherwise stated. We want to clarify that there is no endorsement of the product implied or inferred. This report is not to be copied or reproduced in whole or in part and cannot be used as evidence in a court of law. Legal disputes are subjected to Panchkula jurisdiction only.